Benzene Ring Containing Patents (Class 564/155)
  • Patent number: 9839216
    Abstract: The present invention relates to bis-amide derivatives as defined by the compound of formula (I), to processes and intermediates for preparing them, to methods of using them to control insect, acarine, nematode and mollusc pests, and to insecticidal, acaricidal, nematicidal and molluscicidal compositions comprising them.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: December 12, 2017
    Assignee: Syngenta Participations AG
    Inventors: Thomas Pitterna, Andre Stoller, Andrew Edmunds
  • Patent number: 9422262
    Abstract: The invention relates to the use of a compound of Formula I for the treatment of protease-activated receptor mediated diseases by the administration of a compound of Formula I or a prodrug or metabolite thereof.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: August 23, 2016
    Assignees: The Broad Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Chris Dockendorff, Robert Flaumenhaft
  • Patent number: 9051253
    Abstract: The use of 3,4,3?,4?-tetrahydroxychalcone in the treatment of amyloid diseases, especially A? amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: June 9, 2015
    Assignee: PROTEOTECH INC.
    Inventors: Alan D. Snow, Beth Nguyen, Gerardo Castillo, Virginia Sanders, Thomas Lake, Lesley Larsen
  • Publication number: 20150119426
    Abstract: Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R1, and R2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 30, 2015
    Inventors: Juan Jose Marugan, Jingbo Xiao, Marc Ferrer-Alegre, Catherine Chen, Noel Southall, Wei Zheng, Alexander Agoulnik, Irina Agoulnik
  • Publication number: 20150094294
    Abstract: The present disclosure provides compounds, specifically pyrimidin-4,6-dicarboxylic acid amide derivatives, or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing said compounds. Also provided are methods for treating a mammal having malaria, or killing or inhibiting the growth of a Plasmodium species, comprising administering to said mammal or contacting said Plasmodium species with, an effective amount of a pyrimidin-4,6-dicarboxylic acid amide derivative.
    Type: Application
    Filed: February 28, 2013
    Publication date: April 2, 2015
    Inventors: Richard W. Scott, Robert W. Kavash, Wenxi Pan, Katie Freeman, Michael J. Costanzo, Doron Greenbaum, Yongjiang Xu, Trevor Young
  • Publication number: 20150080472
    Abstract: The invention provides methods of treating Friedreich's ataxia using histone deacetylase inhibitors.
    Type: Application
    Filed: September 9, 2014
    Publication date: March 19, 2015
    Inventors: JOEL M. GOTTESFELD, ANN-KRISTIN JENSSEN, DAVID M. HERMAN, RYAN BURNETT, C. JAMES CHOU
  • Publication number: 20150065721
    Abstract: Provided is a method for producing an aromatic amide derivative represented by Formula (4), the method including a process in which an aromatic amide derivative represented by Formula (1) and a haloalkyl compound represented by Formula (3) are reacted with each other in the presence of a base and a metal or metal salt. In the formulae, each of X and Y represents a hydrogen atom, a halogen atom, or the like. A represents a hydrogen atom, an alkyl group, a group represented by Formula (2), or the like. Each of G1 and G2 represents an oxygen atom or the like. Q1 represents a phenyl group or the like. R1 represents a hydrogen atom, an alkyl group, or the like. Z1 represents a haloalkyl group or the like. Xa represents an iodine atom or the like. m represents a number of from 1 to 4, n1 represents a number from 1 to 5, and n2 represents a number of from 1 to 4.
    Type: Application
    Filed: March 29, 2013
    Publication date: March 5, 2015
    Applicant: Mitsui Chemicals Agro, Inc.
    Inventor: Hironari Okura
  • Publication number: 20150051419
    Abstract: The present invention relates to processes for the preparation of quinoline-3-carboxamide derivatives, such as sodium 5-chloro-3-(ethylphenylcarbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin-4-olate (Laquinimod sodium). The present invention further relates to intermediates formed in such processes.
    Type: Application
    Filed: August 28, 2014
    Publication date: February 19, 2015
    Applicant: MAPI PHARMA LTD.
    Inventors: Ehud MAROM, Michael MIZHIRITSKII, Shai RUBNOV
  • Publication number: 20150045367
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.
    Type: Application
    Filed: December 19, 2012
    Publication date: February 12, 2015
    Inventors: Erik Verner, Wei Chen, Sriram Balasubramanian
  • Publication number: 20150031892
    Abstract: Sphingolipid metabolite mimetics and methods of synthesizing them are provided. The sphingolipid metabolite mimetics are shown to be effective at inducing apoptosis in various types of tumor cells. Further, the sphingolipid metabolite mimetics are shown to be effective at sensitizing multiple types of tumor cells to TRAIL-induced apoptosis. Formulations containing one or more sphingolipid metabolite mimetics and, optionally, one or more cell death receptor agonists are provided. Methods of treating cancer in a subject in need thereof are provided using one or more sphingolipid metabolite mimetics.
    Type: Application
    Filed: October 10, 2014
    Publication date: January 29, 2015
    Inventors: Feiyan Liu, Kebin Liu, Zhizhen Huang, Ping Wu
  • Publication number: 20150011621
    Abstract: Formylated xanthocillin analogs can be used in the treatment of neurodegenerative diseases. The analogs can be prepared synthetically, and at least some of the analogs can be obtained from a microorganism strain of the Penicillium chrysogenum species.
    Type: Application
    Filed: February 2, 2013
    Publication date: January 8, 2015
    Inventors: Maria del Carmen Ramos Martin, Sonia Campoy García, Javier Santos Burgos Muñoz, José Luis Adrio Fondevila, Javier Velasco Alvarez
  • Publication number: 20150005320
    Abstract: The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein X, Y, A, Z, L and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions and immune disorders.
    Type: Application
    Filed: September 27, 2013
    Publication date: January 1, 2015
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Yu Xie, Mats Holmqvist, Jerome Mahiou, Mitsunori Ono, Lijun Sun, Shoujun Chen, Shijie Zhang, Jun Jiang, Dinesh Chimmanamada, Chih-Yi Yu
  • Patent number: 8871208
    Abstract: A method for treating a patient suffering from inflammation, chronic inflammation, pain, rheumatoid arthritis (RA), osteoarthritis and osteoporosis, comprising administering an effective amount of a selective inhibitor of the 11-?-hydroxysteroid dehydrogenase Type 1 enzyme.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: October 28, 2014
    Assignee: AbbVie Inc.
    Inventors: Peer B. Jacobson, Lisa M. Olson, Sreeinvasarao Vepachedu
  • Patent number: 8865771
    Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: October 21, 2014
    Assignee: Vertex Pharamaceuticals Incorporated
    Inventors: Weichuan Caroline Chen, Paul Krenitsky, Andreas Termin, Dean Wilson
  • Publication number: 20140296354
    Abstract: Described herein are the one-pot synthesis and characterization of a library of low molecular weight peptoid compounds that are able to form gels at room temperature. The compounds are synthesized from biologically-based starting materials, are biocompatible, and are resistant to degradation by proteases and peptidases.
    Type: Application
    Filed: April 1, 2014
    Publication date: October 2, 2014
    Applicant: OLD DOMINION UNIVERSITY RESEARCH FOUNDATION
    Inventors: Guijun WANG, Hari P. R. MANGUNURU
  • Patent number: 8835502
    Abstract: The invention provides methods of treating Friedreich's ataxia using histone deacetylase inhibitors.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: September 16, 2014
    Assignee: The Scripps Research Institute
    Inventors: Joel M. Gottesfeld, Kai Jenssen, David M. Herman, Ryan Burnett, C. James Chou
  • Patent number: 8829209
    Abstract: Cycloalkylcarbonylamino acid ester derivatives, which are raw material intermediates for a novel cycloalkane carboxamide derivative having an action that selectively inhibits cathepsin K, and a production process thereof, are provided. A cycloalkylcarbonylamino acid ester derivative represented by formula (I), or a pharmaceutically acceptable salt thereof: (wherein, R1 and R2 represent alkyl groups, alkenyl groups, alkynyl groups, aromatic hydrocarbon groups, heterocyclic groups, etc., R8 represents an alkyl group having 1 to 6 carbon atoms, and ring A represents a cyclic alkylidene group having 5, 6 or 7 carbon atoms).
    Type: Grant
    Filed: January 10, 2007
    Date of Patent: September 9, 2014
    Assignee: Seikagaku Corporation
    Inventors: Nobuo Kobayashi, Tsuneo Koji, Hisatomo Kunii
  • Publication number: 20140248236
    Abstract: The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.
    Type: Application
    Filed: November 7, 2012
    Publication date: September 4, 2014
    Inventors: Michael G. Natchus, Richard Arrendale
  • Patent number: 8791076
    Abstract: The invention relates to compounds of Formula I: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, and R3 are defined as set forth in the specification. The compounds are agonists of neurotrophin (such as nerve growth factor) receptors.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: July 29, 2014
    Inventors: Pablo Villoslada, Angel Messeguer
  • Publication number: 20140206537
    Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.
    Type: Application
    Filed: March 25, 2014
    Publication date: July 24, 2014
    Applicant: DOW AGROSCIENCES LLC
    Inventors: James E. Hunter, William C. Lo, Gerald B. Watson, Akshay Patny, Gary D. Gustafson, Dan Pernich, William K. Brewster, Debra L. Camper, Beth Lorsbach, Michael R. Loso, Thomas C. Sparks, Hemant Joshi, Adiraj Mandaleswaran, Ramadevi Sanam, Rambabu Gundla, Pravin S. Iyer
  • Patent number: 8778221
    Abstract: An aromatic amide compound having the following general formula (I) is provided: wherein, X1 and X2 are independently C(O)HN or NHC(O); G1, G2 and G3 are independently hydrogen, C(O)HN-phenyl, or NHC(O)-phenyl, wherein at least one of G1, G2 and G3 is C(O)HN-phenyl or NHC(O)-phenyl; Q1, Q2, and Q3 are independently hydrogen, C(O)HN-phenyl, or NHC(O)-phenyl, wherein at least one of Q1, Q2, and Q3 is C(O)HN-phenyl or NHC(O)-phenyl; R5 is halo, haloalkyl, alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; and m is from 0 to 4.
    Type: Grant
    Filed: August 27, 2012
    Date of Patent: July 15, 2014
    Assignee: Ticona LLC
    Inventors: Kamlesh P. Nair, Steven D. Gray
  • Patent number: 8779197
    Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: July 15, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Weichuan Caroline Chen, Paul Krenitsky, Pramod Joshi, Andreas Termin, Dean Wilson
  • Patent number: 8778985
    Abstract: Small molecules are used to inhibit specific receptor-ligand interaction between Alzheimer's amyloid-? peptide (A?) and Receptor for Advanced Gly-cation Endproducts (RAGE). Objectives include treating Alzheimer's disease and other pathologies involving cerebral amyloid angiopathy; improving blood flow to or within the brain; decreasing the level of A? in the brain; reducing neuropathology associated with Alzheimer's disease; reducing inflammation and/or oxidant stress in the brain; improving memory and/or learning; treating other conditions involving A?/RAGE interaction at the blood-brain barrier, RAGE-mediated transport of A? into the brain, or RAGE activation in brain vasculature and/or brain parenchyma (e.g., diabetic complications); or any combination thereof.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: July 15, 2014
    Assignee: The University of Rochester
    Inventors: Berislav V. Zlokovic, Rashid Deane, Benjamin L. Miller
  • Publication number: 20140171310
    Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 19, 2014
    Applicant: Dow AgroSciences LLC
    Inventors: William C. Lo, James E. Hunter, Gerald B. Watson, Akshay Patny, Pravin S. Iyer, Joshodeep Boruwa
  • Patent number: 8754129
    Abstract: The present invention relates to crystalline forms of the active pharmaceutical ingredient vorinostat, processes for their preparation and their use in pharmaceutical compositions. Formula (I).
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: June 17, 2014
    Assignee: Generics [UK] Limited
    Inventors: Vinayak Gore, Madhukar Patil, Rahul Bhalerao, Hemant Mande
  • Publication number: 20140165223
    Abstract: Described are methods and compositions for inhibiting the trimerization of ligands belonging to the TNF superfamily, in particular, inhibiting RANKL trimerization. Accordingly, the methods and compositions provided herein can be used to treat disorders associated with increased RANK signaling, in particular those related to bone loss. Compounds that inhibit trimerization of ligands belonging to the TNF superfamily are also described.
    Type: Application
    Filed: February 12, 2014
    Publication date: June 12, 2014
    Applicant: B.S.R.C. "Alexander Fleming"
    Inventors: Eleni Ntouni, Georgios Kollias
  • Patent number: 8748660
    Abstract: The present invention relates to the improved and efficient process for the synthesis of antiepileptic drug Lacosamide in high enantiopurity (>98% ee) and better yield. More particularly, the present invention relates to improved and efficient, cost effective process for synthesis of desired (R) isomer of Lacosamide starting from commercially available (S)-benzyl glycidyl ether.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: June 10, 2014
    Assignee: Council of Scientific & Industrial Research
    Inventors: Muthukrishnan Murugan, Mohammad Mujahid, Prashant Pramod Majumdar
  • Patent number: 8735625
    Abstract: The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: May 27, 2014
    Assignee: Theravance, Inc.
    Inventors: Seok-ki Choi, Paul R. Fatheree, Ryan Hudson, Keith Jendza, Robert Murray McKinnell, Vivek Sasikumar
  • Publication number: 20140142333
    Abstract: Aniline derivatives for anticancer treatment including a compound of the Formula 1, or a derivative thereof, as an active ingredient,
    Type: Application
    Filed: February 4, 2014
    Publication date: May 22, 2014
    Applicant: NEOMICS Co, Ltd.
    Inventors: Sunghoon KIM, Hee Sook Lee, Young Sun Oh, Dae Gyu Kim
  • Patent number: 8716345
    Abstract: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: May 6, 2014
    Assignee: AbbVie Inc.
    Inventors: R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Steven Fung, Peer B. Jacobson, Lynne E. Rueter, Marina I. Strakhova, Jiahong Wang, Jyoti R. Patel, Qi Shuai, James T. Link, Jeffrey J. Rohde, Jurgen Dinges, Bryan K. Sorensen, Martin Winn, Hong Yong, Vince S. Yeh
  • Publication number: 20140117280
    Abstract: An oxygen absorber is provided that contains at least one of compounds each having a particular structure, and the oxygen absorber exhibits an oxygen absorbing capability without a metal contained, and is suitable for removing oxygen inside a packaging material packaging foods or the like.
    Type: Application
    Filed: May 16, 2012
    Publication date: May 1, 2014
    Applicant: MITSUBISHI GAS CHEMICAL COMPANY, INC.
    Inventors: Kentaro Ishii, Ryoji Otaki, Takafumi Oda, Shota Arakawa
  • Patent number: 8710098
    Abstract: A group of amino substituted benzoyl derivatives, their preparation and their use. The screening and research on an antiviral drug with hA3G/Vif as a target point proves that the 3-amino benzoyl derivatives not only have the combined activity for the hA3G/Vif, but also have a function of inhibiting replication of viruses. The present invention provides the possible breakthrough progress for the problem of HIV drug resistance, thereby providing a novel clinical antiviral drug which has higher efficiency.
    Type: Grant
    Filed: September 28, 2009
    Date of Patent: April 29, 2014
    Assignee: Institute of Medicinal Biotechnology Chinese Academy of Medical Science
    Inventors: Jian-Dong Jiang, Liyan Yu, Shan Cen, Zhuorong Li, Yanping Li, Jian Xu
  • Patent number: 8704001
    Abstract: This invention relates to novel 2-amino-3-hydroxypropanoic acid derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an NMDA glycine-site antagonist.
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: April 22, 2014
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Craig E. Masse
  • Publication number: 20140107134
    Abstract: The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein X, Y, A, Z, L and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions and immune disorders.
    Type: Application
    Filed: September 27, 2013
    Publication date: April 17, 2014
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Yu Xie, Mats Holmqvist, Jerome Mahiou, Mitsunori Ono, Lijun Sun, Shoujun Chen, Shijie Zhang, Jun Jiang, Dinesh Chimmanamada, Chih-Yi Yu
  • Patent number: 8697911
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: April 15, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Brian Nicholas Cook, Jennifer A. Kowalski, Xiang Li, Daniel Richard Marshall, Sabine Schlyer, Robert Sibley, Lana Louise Smith-Keenan, Fariba Soleymanzadeh, Ronald John Sorcek, Erick Richard Roush Young, Yunlong Zhang
  • Patent number: 8686045
    Abstract: Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: April 1, 2014
    Assignees: The University of North Carolina at Chapel Hill, The Regents of the University of California, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Frank M. Longo, Stephen M. Massa
  • Patent number: 8674134
    Abstract: Disclosed herein is a sequential functionalization methodology for the covalent modification of nanotubes with between one and four repeat units of a polymer. Covalent attachment of oligomer units to the surface of nanotubes results in oligomer units forming an organic sheath around the nanotubes, polymer-functionalized-nanotubes (P-NTs). P-NTs possess chemical functionality identical to that of the functionalizing polymer, and thus provide nanoscale scaffolds which may be readily dispersed within a monomer solution and participate in the polymerization reaction to form a polymer-nanotube/polymer composite. Formation of polymer in the presence of P-NTs leads to a uniform dispersion of nanotubes within the polymer matrix, in contrast to aggregated masses of nanotubes in the case of pristine-NTs.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: March 18, 2014
    Assignee: The Regents of the University of California
    Inventors: Alexander K. Zettl, Toby Sainsbury, Jean M. J. Fréchet
  • Publication number: 20140031370
    Abstract: A compound represented by Formula (1): The compound can be used as insecticides.
    Type: Application
    Filed: September 20, 2013
    Publication date: January 30, 2014
    Applicant: MITSUI CHEMICALS, INC.
    Inventors: Kei Yoshida, Takeo Wakita, Hiroyuki Katsuta, Akiyoshi Kai, Yutaka Chiba, Kiyoshi Takahashi, Hiroko Kato, Nobuyuki Kawahara, Michikazu Nomura, Hidenori Daido, Junji Maki, Shinichi Banba
  • Publication number: 20130331411
    Abstract: The invention relates to the use of a compound of Formula I for the treatment of protease-activated receptor mediated diseases by the administration of a compound of Formula I or a prodrug or metabolite thereof.
    Type: Application
    Filed: September 23, 2011
    Publication date: December 12, 2013
    Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, THE BROAD INSTITUTE, INC.
    Inventors: Chris Dockendorff, Robert Flaumenhaft, Lawrence MacPherson
  • Publication number: 20130310459
    Abstract: An amide derivative represented by the following Formula (1) is provided as an amide derivative showing a significantly excellent effect for a pest control action. In the following Formula (1), A represents a carbon atom, a nitrogen atom, or the like, and K represents a non-metal atomic group necessary for forming a cyclic linking group derived from benzene or a heterocyclic. X represents a halogen atom or the like; n represents an integer of from 0 to 4. R1 and R2 represent hydrogen atoms, alkyl groups, or the like. T represents —C(=G1)-Q1 or —C(=G1)-G2Q2, and G1 to G3 each represent oxygen atoms or the like. Q1 and Q2 each represent a hydrogen atom, an alkyl group, an aryl group, or the like. Y1 and Y5 each represent a halogen atom or the like, Y2 and Y4 each represent a hydrogen atom or the like, and Y3 represents a C2-C5 haloalkyl group.
    Type: Application
    Filed: July 24, 2013
    Publication date: November 21, 2013
    Applicant: Mitsui Chemicals Agro, Inc.
    Inventors: Yumi Kobayashi, Hidenori Daido, Hiroyuki Katsuta, Michikazu Nomura, Hidetaka Tsukada, Atsushi Hirabayashi, Yusuke Takahashi, Yoji Aoki, Atsuko Kawahara, Yasuaki Fukazawa, Mai Hirose
  • Patent number: 8563736
    Abstract: A compound represented by Formula (1): The compound can be used as insecticides.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: October 22, 2013
    Assignee: Mitsui Chemicals, Inc.
    Inventors: Kei Yoshida, Takeo Wakita, Hiroyuki Katsuta, Akiyoshi Kai, Yutaka Chiba, Kiyoshi Takahashi, Hiroko Kato, Nobuyuki Kawahara, Michikazu Nomura, Hidenori Daido, Junji Maki, Shinichi Banba
  • Publication number: 20130245275
    Abstract: The present invention relates to phenyl diamides according to the general formula (1) and their use as a medicament and a pharmaceutical preparation comprising as an active ingredient a phenyl diamide according to the general formula (1). Further, the present invention relates to phenyl diamides according to the formulas (16), (17) and (18) for use in the treatment of gliomas.
    Type: Application
    Filed: October 4, 2011
    Publication date: September 19, 2013
    Applicant: Rheinische Friedrich-Wilhelms Universitaet Bonn
    Inventors: Michael Famulok, Anke Bill, Anton Schmitz, Juergen Bajorath
  • Publication number: 20130245257
    Abstract: The invention provides a compound having a heterocyclic skeleton of formula (I): wherein the substituents are as defined in the specification, as well as a tautomer thereof or a salt thereof. The invention also provides asymmetric synthesis methods involving the use of such a compound, tautomer thereof, or salt thereof, as a catalyst.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 19, 2013
    Applicants: Sumitomo Chemical Company, Limited, Kyoto University
    Inventors: Yoshiji TAKEMOTO, Kazuo MURAKAMI
  • Publication number: 20130244944
    Abstract: Provided herein are self-assembling compounds that can form ion channels in lipid bilayers or cell membranes and ion-channel-forming compositions comprising the self-assembling compounds. Also provided are methods of making and using the ion channels formed from a plurality of molecules of the self-assembling compounds. Further, provided are methods of treating or preventing conditions and diseases that are related to the dysfunction of ion channels, including chloride channels.
    Type: Application
    Filed: December 31, 2012
    Publication date: September 19, 2013
    Applicants: VERSITECH LIMITED, THE UNIVERSITY OF HONG KONG
    Inventors: Dan Yang, Xiang Li, Huiyan Zha
  • Publication number: 20130231392
    Abstract: An amide derivative represented by the following Formula (1) is provided as an amide derivative showing a significantly excellent effect for a pest control action. In the following Formula (1), A represents a carbon atom, a nitrogen atom, or the like, and K represents a non-metal atomic group necessary for forming a cyclic linking group derived from benzene or a heterocyclic. X represents a halogen atom or the like; n represents an integer of from 0 to 4. R1 and R2 represent hydrogen atoms, alkyl groups, or the like. T represents —C(=G1)-Q1 or —C(=G1)-G2Q2, and G1 to G3 each represent oxygen atoms or the like. Q1 and Q2 each represent a hydrogen atom, an alkyl group, an aryl group, or the like. Y1 and Y5 each represent a halogen atom or the like, Y2 and Y4 each represent a hydrogen atom or the like, and Y3 represents a C2-C5 haloalkyl group.
    Type: Application
    Filed: March 18, 2013
    Publication date: September 5, 2013
    Applicant: MITSUI CHEMICALS ARGO, INC.
    Inventors: Yumi Kobayashi, Hidenori Daido, Hiroyuki Katsuta, Michikazu Nomura, Hidetaka Tsukada, Atsushi Hirabayashi, Yusuke Takahashi, Yoji Aoki, Atsuko Kawahara, Yasuaki Fukazawa, Mai Hirose
  • Patent number: 8518999
    Abstract: The present invention provides compounds which are modulators of TNF-? signaling and methods of use thereof for treating a patient having a TNF-? mediated condition.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: August 27, 2013
    Assignee: Genzyme Corporation
    Inventors: Scott F. Sneddon, John L. Kane, Bradford H. Hirth, Fred Vinick, Shuang Qiao, Sharon R. Nahill, John M. Williams, Hans-Peter Biemann
  • Publication number: 20130217660
    Abstract: Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.
    Type: Application
    Filed: May 12, 2011
    Publication date: August 22, 2013
    Inventors: Dong-Ming Shen, John S. Debenham, Thomas H. Graham, Matthew J. Clements, Yong Zhang
  • Patent number: 8487130
    Abstract: Described is a new cooling agent represented by Structure I and compositions with known coolers having cooling properties and the application of Structure I in foodstuffs and chewing gum:
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: July 16, 2013
    Assignee: International Flavors & Fragrances Inc.
    Inventors: Arkadiusz Kazimierski, Mark L. Dewis
  • Publication number: 20130172388
    Abstract: Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof: wherein: R1 and R2 are independently H, alkyl, or alkenyl; R3 is alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; R4 and R5 are independently a bond, alkylenyl, or alkenylenyl; each R6 and R7 is independently selected from the group consisting of OH, F, Cl, Br, I, (C1-C6)alkyl, alkoxy, amino, COOH, CONH2, SO3H, PO3H2, CN, SH, NO2 and CF3; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.
    Type: Application
    Filed: December 14, 2012
    Publication date: July 4, 2013
    Applicant: University of Pittsburgh -- Of the Commonwealth System of Higher Education
    Inventor: University of Pittsburgh -- Of the Commonwealth System of Higher Education
  • Patent number: RE44510
    Abstract: The invention relates to tuned multifunctional linker molecules for charge transport through organic-inorganic composite structures. The problem underlying the present invention is to provide multifunctional linker molecules for tuning the conductivity in nanoparticle-linker assemblies which can be used in the formation of electronic networks and circuits and thin films of nanoparticles. The problem is solved according to the invention by providing a multifunctional linker molecule of the general structure CON1-FUNC1-X-FUNC2-CON2 in which X is the central body of the molecule, FUNC1 and FUNC2 independently of each other are molecular groups introducing a dipole moment and/or capable of forming inter-molecular and/or intramolecular hydrogen bonding networks, and CON1 and CON2 independently of each other are molecular groups binding to nanostructured units comprising metal and semiconductor materials.
    Type: Grant
    Filed: September 15, 2012
    Date of Patent: September 24, 2013
    Assignee: Sony Deutschland GmbH
    Inventors: Jurina Wessels, William E. Ford, Akio Yasuda